ZA200601360B - Pharmaceutical formulation containing an LTB4 antagonist, method for the production thereof, and use thereof - Google Patents
Pharmaceutical formulation containing an LTB4 antagonist, method for the production thereof, and use thereofInfo
- Publication number
- ZA200601360B ZA200601360B ZA200601360A ZA200601360A ZA200601360B ZA 200601360 B ZA200601360 B ZA 200601360B ZA 200601360 A ZA200601360 A ZA 200601360A ZA 200601360 A ZA200601360 A ZA 200601360A ZA 200601360 B ZA200601360 B ZA 200601360B
- Authority
- ZA
- South Africa
- Prior art keywords
- production
- pharmaceutical formulation
- formulation containing
- ltb4 antagonist
- ltb4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10350528A DE10350528A1 (de) | 2003-10-29 | 2003-10-29 | Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200601360B true ZA200601360B (en) | 2007-03-28 |
Family
ID=34529886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200601360A ZA200601360B (en) | 2003-10-29 | 2006-02-15 | Pharmaceutical formulation containing an LTB4 antagonist, method for the production thereof, and use thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050129768A1 (fr) |
EP (1) | EP1682086A2 (fr) |
JP (1) | JP2007513068A (fr) |
KR (1) | KR20060108696A (fr) |
CN (1) | CN101123950A (fr) |
AU (1) | AU2004285271A1 (fr) |
BR (1) | BRPI0416121A (fr) |
CA (1) | CA2544049A1 (fr) |
DE (1) | DE10350528A1 (fr) |
IL (1) | IL175293A0 (fr) |
MX (1) | MXPA06004435A (fr) |
RU (1) | RU2006118273A (fr) |
WO (1) | WO2005041855A2 (fr) |
ZA (1) | ZA200601360B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2560165A1 (fr) * | 2004-05-04 | 2005-11-10 | Boehringer Ingelheim International Gmbh | Forme pharmaceutique solide comprenant un antagoniste ltb4 |
US20200199168A1 (en) | 2017-05-12 | 2020-06-25 | Riken | Class a gpcr-binding compound modifier |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4424713A1 (de) * | 1994-07-13 | 1996-01-18 | Boehringer Ingelheim Kg | Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe |
JP2000178204A (ja) * | 1998-10-05 | 2000-06-27 | Eisai Co Ltd | ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤 |
WO2000020033A1 (fr) * | 1998-10-05 | 2000-04-13 | Eisai Co., Ltd. | Comprimes se delitant immediatement dans la cavite buccale |
JP2000191518A (ja) * | 1998-10-19 | 2000-07-11 | Eisai Co Ltd | 溶解性の改善された口腔内速崩壊性錠剤 |
DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
KR100381834B1 (ko) * | 2000-05-20 | 2003-04-26 | 이상득 | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
-
2003
- 2003-10-29 DE DE10350528A patent/DE10350528A1/de not_active Withdrawn
-
2004
- 2004-10-23 WO PCT/EP2004/012015 patent/WO2005041855A2/fr active Application Filing
- 2004-10-23 AU AU2004285271A patent/AU2004285271A1/en not_active Abandoned
- 2004-10-23 BR BRPI0416121-1A patent/BRPI0416121A/pt not_active IP Right Cessation
- 2004-10-23 CA CA002544049A patent/CA2544049A1/fr not_active Abandoned
- 2004-10-23 EP EP04790806A patent/EP1682086A2/fr not_active Withdrawn
- 2004-10-23 KR KR1020067010481A patent/KR20060108696A/ko not_active Application Discontinuation
- 2004-10-23 MX MXPA06004435A patent/MXPA06004435A/es not_active Application Discontinuation
- 2004-10-23 JP JP2006537151A patent/JP2007513068A/ja active Pending
- 2004-10-23 RU RU2006118273/15A patent/RU2006118273A/ru not_active Application Discontinuation
- 2004-10-23 CN CNA2004800322902A patent/CN101123950A/zh active Pending
- 2004-10-29 US US10/977,035 patent/US20050129768A1/en not_active Abandoned
-
2006
- 2006-02-15 ZA ZA200601360A patent/ZA200601360B/xx unknown
- 2006-04-27 IL IL175293A patent/IL175293A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005041855A3 (fr) | 2007-05-10 |
RU2006118273A (ru) | 2007-12-20 |
DE10350528A1 (de) | 2005-06-09 |
EP1682086A2 (fr) | 2006-07-26 |
MXPA06004435A (es) | 2006-06-20 |
WO2005041855A2 (fr) | 2005-05-12 |
US20050129768A1 (en) | 2005-06-16 |
CN101123950A (zh) | 2008-02-13 |
BRPI0416121A (pt) | 2007-01-02 |
CA2544049A1 (fr) | 2005-05-12 |
JP2007513068A (ja) | 2007-05-24 |
KR20060108696A (ko) | 2006-10-18 |
AU2004285271A1 (en) | 2005-05-12 |
IL175293A0 (en) | 2006-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1167332A1 (en) | Pharmaceutical composition, use thereof and method for making the same | |
TWI347201B (en) | Pharmaceutical products,uses thereof and methods for preparing the same | |
PL378065A1 (pl) | Podstawione związki N-aryloheterocykliczne, sposób ich wytwarzania oraz ich zastosowanie jako środków leczniczych | |
IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
IL168056A0 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
IL191926A0 (en) | Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof | |
HK1094433A1 (en) | Flocculating agent, method for the production and use thereof | |
HK1081965A1 (en) | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | |
IL175127A0 (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
IL162669A0 (en) | Antichlinergic agents, method for producing the same and use thereof as medicaments | |
HK1099748A1 (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same | |
PL394600A1 (pl) | Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna | |
HUP0401522A2 (en) | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation | |
PL377741A1 (pl) | Pochodne diarylocykloalkilowe, sposób ich wytwarzania i ich zastosowanie jako środka leczniczego | |
HUP0303948A2 (hu) | Szájban diszpergálódó szilárd gyógyszerforma | |
GB0316206D0 (en) | Pharmaceutical formulation | |
IL165213A0 (en) | Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same | |
IL174975A0 (en) | 2-phenyl-benzofuran derivatives, method for the production thereof and their use | |
IL173918A0 (en) | Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same | |
IL175293A0 (en) | Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof | |
IL174081A0 (en) | Formulation for obtaining a pharmaceutical composition, methods of obtaining and use thereof | |
EP1515960A4 (fr) | Derive de 2-thioxothiazole, procede de preparation de ce derive et composition pharmaceutique contenant ce derive | |
EP1693067A4 (fr) | Composition pharmaceutique anti-herpetique, procede de production d'une forme medicamenteuse a partir de cette composition et procede d'utilisation correspondant | |
EP1506180A4 (fr) | Derive de thiazolidine-4-one, procede d'elaboration, et composition pharmaceutique a base de ce derive |